世界の医薬品連続製造市場 – 2031 年までの業界動向と予測

医薬品連続製造市場の分析と規模

世界の医薬品連続製造市場は、コスト効率、効率性、規制サポートによって推進されています。連続製造により、合理化された製造プロセス、一貫した製品品質、市場投入までの時間の短縮が保証されます。連続製造は、錠剤製造、造粒、コーティング、統合プロセス制御に応用され、世界中の製薬会社にサプライ チェーンの統合と強化されたトレーサビリティを提供します。

Data Bridge Market Researchは、世界の医薬品連続製造市場は2023年に28億6,000万米ドルの価値で成長し、2031年には53億5,000万米ドルの価値に達し、2024年から2031年にかけて8.16%のCAGRを記録すると分析しています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、Data Bridge Market Researchチームがまとめた市場レポートには、詳細な専門家分析、輸入/輸出分析、価格分析、生産消費分析、特許分析、消費者行動が含まれています。  

レポートの範囲と市場セグメンテーション      

市場の定義

医薬品の連続製造とは、医薬品を中断することなく連続的に製造する生産方法です。原材料を錠剤、カプセル、その他の剤形などの完成品に合理的かつ統合的に処理します。

世界の医薬品連続製造市場の動向

ドライバー

• 医薬品の連続製造はコスト削減を促進する  

医薬品の連続製造は、業務の最適化、労働力の削減、エネルギー消費の削減、材料の無駄の最小化によってコスト削減を促進します。中断のないプロセスにより効率とリソースの利用度が向上し、製薬会社の収益性と競争力が向上します。これらの利点により、収益と市場での地位の向上を目指す企業にとって、連続製造は戦略的な選択肢となります。

• 連続製造により資源効率を向上

連続製造は、生産サイクル間のダウンタイムを最小限に抑え、機器の使用率を最適化し、手動介入の必要性を減らすことで、リソース効率を高めます。 連続プロセスにより、製薬会社は業務を合理化し、無駄を減らし、リソースをより効果的に活用できます。 自動化と高度な制御システムを統合することで、連続製造はパラメータの正確な監視と調整を保証し、製品の品質と一貫性を維持しながらリソースの使用率を最大化し、最終的に全体的な運用効率を向上させます。

機会

• 連続製造の導入を奨励する規制当局

Regulatory agencies, such as the FDA and EMA, are encouraging the adoption of continuous manufacturing to enhance drug quality, ensure consistent product standards, and expedite drug development and approval processes. Their endorsement stems from the method's capacity to enhance process control and product quality monitoring, thus minimizing variations. By encouraging its adoption, regulatory bodies aim to modernize manufacturing practices, boost efficiency, and maintain stringent quality standards across the pharmaceutical industry, thereby fostering market growth and widespread adoption.

• Increased Efficiency and Productivity by Continuous Manufacturing Processes

Continuous manufacturing processes transform efficiency in pharmaceutical production by drastically cutting production cycle times, minimizing manual interventions, and boosting overall productivity in contrast to traditional batch manufacturing. By streamlining operations and eliminating batch-related downtimes, continuous processes ensure seamless production flows and rapid product turnaround. Automation and real-time monitoring further enhance efficiency, enabling immediate adjustments and quality assurance measures. Consequently, pharmaceutical companies can meet market demands swiftly, reduce costs, and maintain high-quality standards, enhancing competitiveness in the industry.

Restraints/Challenges

• Risk of Technology Failure Impact Production Efficiency

Continuous manufacturing systems are reliant on automation, control systems, and software platforms, which may be prone to technical glitches, software failures, or equipment malfunctions. The risk of technology failure and process disruptions can impact production efficiency, product quality, and regulatory compliance, posing risks to patient safety and business continuity.

• Initial Investment Costs

Implementing continuous manufacturing requires significant upfront investment in equipment, technology upgrades, staff training, and process validation. The high initial costs associated with transitioning from traditional batch manufacturing to continuous processes may deter some pharmaceutical companies from adopting these technologies.

This global pharmaceutical continuous manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pharmaceutical continuous manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In March 2022, USP India extended its presence in Hyderabad, announcing plans for a new continuous manufacturing facility with an added capital injection of USD 20 million. This expansion underscores USP's commitment to enhancing its operations and services in India's pharmaceutical sector
• In March 2022, Phlow Corp, a U.S. based public benefit company specializing in essential medicines, partnered with Virginia Commonwealth University (VCU) Medicines for All Institute and AMPAC Fine Chemicals. The collaboration aims to offer contract research and development services for small molecule pharmaceutical products, focusing on continuous manufacturing, thereby bolstering the pharmaceutical industry's capabilities and innovation

Global Pharmaceutical Continuous Manufacturing Market Scope

The global pharmaceutical continuous manufacturing market is segmented into four notable segments based on product type, application type, distribution channel, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Integrated Systems
•  Semi-Continuous Systems
• Controls
• Continuous Granulators
• Continuous Coaters
• Continuous Blenders
• Continuous Dryers
• Other semi-continuous Systems

Application Type

•  Active Pharmaceutical Ingredient
•  Dry Powders
• Biologics
• End Product Manufacturing
• Solid Dosage

Distribution Channel

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy

End User

• Research and Development Departments
•  Full-Scale Manufacturing Companies
• Contact Manufacturing Organizations (CMOs)
• Pharmaceuticals Companies
• Research Institutes
• Contact Research Organizations (CROs)

Global Pharmaceutical Continuous Manufacturing Market Regional Analysis/Insights

The global pharmaceutical continuous manufacturing market is analysed and market size insights and trends are provided by based on product type,  application type,  distribution channel, and end user as referenced above.

The countries covered in the global pharmaceutical continuous manufacturing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

Europe dominates the global pharmaceutical continuous manufacturing market due to its stringent regulatory environment, fostering innovation and adoption of advanced manufacturing techniques. The region boasts a well-established pharmaceutical industry, extensive research infrastructure, and strong support for technological development.

Asia-Pacific is the fastest-growing region in the global pharmaceutical continuous manufacturing market due to increasing investments in pharmaceutical manufacturing infrastructure, rising adoption of advanced technologies, expanding pharmaceutical markets, growing demand for affordable healthcare solutions, and supportive government initiatives promoting innovation and development in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pharmaceutical Continuous Manufacturing Market Share Analysis

The global pharmaceutical continuous manufacturing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pharmaceutical continuous manufacturing market.

Some of the major players operating in the global pharmaceutical continuous manufacturing market are:

• GEA Group Aktiengesellschaft (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Hosokawa Micron B.V. (Japan)
• Robert Bosch GmbH 9Germeany)
• Glatt GmbH (India)
• Siemens (Germany)
• Coperion GmbH (Germany)
• Aurobindo Pharma (India)
• L.B. Bohle Maschinen und Verfahren GmbH (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Sanofi (France)

SKU-60039